Anixa Biosciences is a biotechnology company. Co.'s vaccine programs include: the development of a preventative vaccine against triple negative breast cancer and other forms of breast cancer; and the development of a preventative vaccine against ovarian cancer. Co.'s therapeutics programs include: the development of a chimeric endocrine receptor T-cell therapy, a form of chimeric antigen receptor T-cell technology, initially focused on treating ovarian cancer, which is being developed at its subsidiary, Certainty Therapeutics, Inc.; and the development of anti-viral drug candidates for the treatment of Coronavirus disease 2019 focused on inhibiting certain protein functions of the virus. We show 19 historical shares outstanding datapoints in our coverage of ANIX's shares outstanding history.
Understanding the changing numbers of ANIX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ANIX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ANIX by allowing them to research ANIX shares outstanding history
as well as any other stock in our coverage universe. |
Free ANIX Email Alerts:
Video: Shares Outstanding Importance
